HaTay Pharmaceutical JSC
VN:DHT
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
22 100
82 000
|
| Price Target |
|
We'll email you a reminder when the closing price reaches VND.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
HaTay Pharmaceutical JSC
Accounts Receivables
HaTay Pharmaceutical JSC
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
HaTay Pharmaceutical JSC
VN:DHT
|
Accounts Receivables
₫110.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
7%
|
|
|
I
|
Imexpharm Corp
VN:IMP
|
Accounts Receivables
₫357.3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
15%
|
CAGR 10-Years
8%
|
|
|
C
|
Cuu Long Pharmaceutical JSC
VN:DCL
|
Accounts Receivables
₫266.5B
|
CAGR 3-Years
18%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
D
|
Domesco Medical Import Export Joint Stock Corp
VN:DMC
|
Accounts Receivables
₫706.9B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
9%
|
|
|
D
|
Dhg Pharmaceutical Joint-Stock Co
VN:DHG
|
Accounts Receivables
₫446.4B
|
CAGR 3-Years
19%
|
CAGR 5-Years
2%
|
CAGR 10-Years
0%
|
|
|
T
|
Traphaco JSC
VN:TRA
|
Accounts Receivables
₫257.7B
|
CAGR 3-Years
13%
|
CAGR 5-Years
13%
|
CAGR 10-Years
2%
|
|
HaTay Pharmaceutical JSC
Glance View
Ha Tay Pharmaceutical JSC engages in the manufacture, import and export of drugs, medicine, cosmetic and medical equipment. The company is headquartered in Hanoi, Hanoi. The company went IPO on 2008-12-03. The company is engaged in the manufacturing, marketing, wholesale and retail trading, import and export of pharmaceutical products, preparations and materials, vaccines, along with medical equipment and supplies. The firm also manufactures and trades cosmetic products, supplemental food, general chemicals and specialized chemicals for laboratory tests. Other activities include supermarket operations, office and apartment leasing, real estate brokerage services, as well as the provision of vocational training services. The firm announced that it has completed the acquisition of 50.626% stake in Ha Tay Pharmaceutical and Medical Equipments Joint Stock Company by the end of the third quarter of 2013.
See Also
What is HaTay Pharmaceutical JSC's Accounts Receivables?
Accounts Receivables
110.6B
VND
Based on the financial report for Sep 30, 2024, HaTay Pharmaceutical JSC's Accounts Receivables amounts to 110.6B VND.
What is HaTay Pharmaceutical JSC's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
7%
Over the last year, the Accounts Receivables growth was 3%. The average annual Accounts Receivables growth rates for HaTay Pharmaceutical JSC have been -2% over the past three years , -7% over the past five years , and 7% over the past ten years .
You don't have any saved screeners yet
